Share
EAST LANSING, Mich. — CircNova, a Detroit-based biotechnology company, has secured an investment from Michigan Rise Pre-Seed Fund III as part of the Company’s pre-seed financing round.
CircNova uses their proprietary artificial intelligence (AI) engine to predict and design the structure of circular, non-coding RNA (ncRNA) sequences for the purpose of generating novel RNA therapeutics which have the potential to treat diseases caused by traditionally undruggable targets. The company is led by co-founders Crystal Brown (CEO), Steven Schwartz (CTO) and Joseph DeAngelo (CSO).
“CircNova’s AI NovaEngine™ platform has the potential to enable entirely new therapeutic paradigms utilizing circular, ncRNA by addressing major challenges which currently exist in the field around predicting the structure and function of non-coding RNA sequences. Their platform can provide major competitive advantages to biotech companies in terms of the speed and precision of their drug discovery processes,” said Matt Okoneski, Senior Venture Associate at Michigan Rise. “CircNova’s focus on advancing the field of circular, ncRNA-based therapeutics puts the company on the forefront of programmable medicine.”
The investment from Michigan Rise will support CircNova’s R&D operations as well as facilitate future staffing initiatives.